Pages

▼
Friday, December 30, 2011

Dicerna Ends Year on Positive Note

›
With the Notice of Allowance of a US patent application covering its basic Dicer-substrate RNAi trigger technology and a $5M milestone pa...
Wednesday, December 28, 2011

Gradalis Swiftly Moves ddRNAi-Enhanced Cancer Vaccine Candidate through Clinic

›
I’ve been reminded a number of times by the staunch Benitec-supporters here that Texas-based biotech company Gradalis has been moving a ddRN...
20 comments:
Tuesday, December 13, 2011

Mr. Anonymous Thwarted in Zamore US Patent Re-exam

›
Silence Therapeutics reported that a number of valuable RNAi trigger patents related to the Zamore Design Rules that were issued last year ...
18 comments:
Saturday, December 10, 2011

Alnylam General Counsel Has Left Company

›
According to Linked in , Alnylam's General Counsel, Philip Chase, has just left the company to become General Counsel of Adimab [ note: ...
4 comments:
Friday, December 9, 2011

What Business Does Alnylam’s Counsel Have at the City of Hope?

›
The Tekmira and Alnylam dispute is a classical David versus Goliath encounter. By my standards, Protiva/Tekmira clearly deserves credit for...
11 comments:
Thursday, December 8, 2011

SNALP RNAi versus RNaseH Antisense for Gene Knockdown in the Liver

›
Following recent phase I results from ISIS Pharmaceutical’s Factor XI (ASH abstract 12999; addendum: PR on phase I data reported on Decembe...
8 comments:
Wednesday, November 30, 2011

SNALP Delivery Keeps On Giving: Tekmira Receives OK for Ebola Clinical Studies

›
On Monday, Tekmira announced that it has received the Green Light from the FDA to go ahead with clinical studies of its SNALP-enabled biode...
12 comments: